Pfizer announces second-generation EGFR-tyrosine kinase inhibitor target drug Dacutinib (Dozerun ®) officially launched in China

lung cancer ranks first in the morbidity and mortality of all types of cancer in ChinaOf these, NSCLC accounts for about 85% of all lung cancer casesIn China, EGFR is the most common type of mutation, with advanced EGFR mutation accounting for about 50%recently, Pfizer announced that the second generation of EGFR-tyrosine kinase inhibitors (TKI) targeteddrug(http://Dacostini (commodity name: Dozerun ®) officially landed in China, while launching the "EAR Lung Cancer Precision Institute" to bring new precision treatment programs for lung cancer patientsOn May 15 this year, Dacostinib was approved by the NationalMedicines(http://Regulatory Authority (NMPA) of China, and can be used as a single drug for first-line treatment of patients with late-stage or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) 19 epidermal osteocrinatic deficiency mutation son or 21 exon L858R displacement mutationSeptember 2018, the U.SFood and Drug Administration (
FDA(http://) granted the first-line treatment of Dacosti to patients with advanced or metastatic EGFR mutations in NSCLC, Dakota nini has been approved for first-line treatment for advanced lung cancer in the United States, the European Union, Japan, Canada, etc., and has been granted applications almost simultaneously with the world in China and approved by regulators